Research programme: Anti-BCMA CAR-based NK cell therapies - ImmunityBio
Alternative Names: Research programme: Anti-BCMA chimeric antigen receptor-based NK cell therapies - ImmunityBio; Research programme: chimeric antigen receptor-based NK cell therapies - ImmunityBioLatest Information Update: 28 Apr 2023
At a glance
- Originator NantKwest
- Developer ImmunityBio
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for research development in Multiple-myeloma in USA (Parenteral)
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 04 Mar 2019 NantKwest in-licenses B-Cell Maturation Antigen targeted antibody sequence from ProMab Biotechnologies